Home > News > Asklepios Bio and Bayer Healthcare Sign Research Deal
June 3rd, 2005
Asklepios Bio and Bayer Healthcare Sign Research Deal
Abstract:
Asklepios is currently conducting preclinical testing of a synthetically designed biological nano particle (BNP) gene therapy, containing the factor IX gene for the treatment of hemophilia B.
Source:
triangletechjournal.com
Bookmark:
| Related Links |
Asklepios Biopharmaceutical Inc.
| Related News Press |
Investments/IPO's/Splits
Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017
Nanomedicine
Physicists make quantum leap in understanding life's nanoscale machinery June 27th, 2017
Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017
Learning with light: New system allows optical “deep learning”: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017
Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017
Announcements
Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017
NMRC, University of Nottingham chooses the Quorum Q150 coater for its reliable and reproducible film thickness when coating samples with iridium June 27th, 2017
Picosun’s ALD solutions enable novel high-speed memories June 27th, 2017
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||